ChatGPT Stock Advice: AbbVie Inc. (ABBV) Among Top Stock Recommendations

We recently published a list of ChatGPT Stock Advice: Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations by ChatGPT.

After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by uncertainties surrounding the escalating trade wars. As of the close of business on May 2, the broad market index was down by 3.31% year-to-date.

READ ALSO: 11 Worst Performing Stocks in S&P 500 So Far in 2025 and 15 Stocks ChatGPT Predicts Could Make You Wealthy in 10 Years.

A New York-based investment banking firm recently projected positive but muted returns for 2025. However, it added that the continued adoption of AI could lead to a strong rally. The company also pointed out how bull markets have historically produced mediocre results in the third year, although not usually negative.

Trends over the past decades also show that sustained high returns are uncommon. Following the strong back-to-back performance in the 1920s, markets went down sharply in 1929, marking the beginning of the Great Depression. Then, after recovering in 1935 and 1936, they took a giant step back again a year later.

Over the years, many investors have turned toward ChatGPT for investment advice, including how the markets would respond to news headlines, statements from the Federal Reserve, or any other event that could cause share price movements. A 2023 survey revealed that about 53% of the Millennials, 50% of Gen Z, and 46% of  Gen X respondents had used the AI chatbot for investing advice.

In contrast, older Americans were found to be more skeptical of the recommendations, with just 25% of the Baby Boomers using ChatGPT to buy stocks. Collectively, about 47% of all survey respondents had used the platform for stock recommendations. Among them, 69% stated they would consider using ChatGPT for investment advice in the future as well.

While the reliability of ChatGPT to provide accurate and up-to-date information has repeatedly come under question from most financial analysts, a professor at the University of Florida in 2023 claimed that the chatbot may be able to predict stock movements. Alejandro Lopez-Lira used the platform to parse negative and positive headlines for stocks and predict returns for the following day, and was surprised to find how good the results were.

Whether or not tools like ChatGPT are effective in stock recommendations remains a debate. However, they can be useful for new investors looking for financial education and researching companies they want to invest in.

Our Methodology

For this list, we prompted ChatGPT to recommend the top 12 stocks based on its assessment of historical trends and the current market situation. The stocks are ranked in this article in the same order as provided by ChatGPT. The platform said it based its rankings on several factors, including long-term past performance, innovation capacity, economic resilience, and current macroeconomic trends.

For perspective, we have also shared the hedge fund sentiment toward each stock, based on Insider Monkey’s database of over 1,000 prominent hedge funds as of Q4 2024.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 85

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that is engaged in the manufacturing and sale of various medicines and therapies. Its product portfolio includes aesthetics, eye care, immunology, oncology, neuroscience, and other key products. It is among the best companies to invest in, according to ChatGPT’s stock advice.

On April 25, AbbVie Inc. (NYSE:ABBV) declared impressive financial results for the first quarter of fiscal 2025, exceeding expectations across several of its therapeutic areas. The company reported total net revenues of over $13.3 billion, growing 9.8% on an operational basis from last year. It delivered adjusted diluted EPS of $2.46, a year-over-year increase of 6.5% and 10 cents above ABBV’s guidance midpoint.

AbbVie Inc. (NYSE:ABBV) raised its adjusted diluted EPS guidance for the full year to $12.09 to $12.29, from the initial range of between $11.99 and $12.19 per share. Following the earnings call, Morgan Stanley raised the stock’s price target from $241 to $250 per share, while maintaining the Overweight rating for the stock.

Another recent development riding the positive wave around AbbVie Inc. (NYSE:ABBV) is the FDA approval for RINVOQ (upadacitinib) for the treatment of adults with giant cell arthritis. This follows the recent market authorization of RINVOQ by the European Commission for treating adult patients.

Wall Street analysts are bullish on AbbVie Inc. (NYSE:ABBV) with a consensus Buy rating and an average share price upside potential of nearly 7%. According to Insider Monkey’s database for Q4 2024, 85 hedge funds held a stake in the company.

Overall, ABBV ranks 11th among ChatGPT Stock Advice: Top 12 Stock Recommendations. While we acknowledge the potential of ABBV as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires

Disclosure: None. This article is originally published at Insider Monkey.